ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Preclinical

Melanotan I

Melanotan I

Also known as: MT-1, MT-I, Afamelanotide, Scenesse, CUV1647, [Nle4, D-Phe7]-alpha-MSH

Overview

Key Facts

Primary Goal: Research and therapeutic applications of Melanotan I

Potently and selectively agonizes MC1R on melanocytes, stimulating eumelanin synthesis via cAMP/PKA/MITF pathway. Partial agonism at MC4R contributes to mild pro-sexual and anorexigenic effects.

Dosing Information

Half-Life

~30-50 minutes

Typical Dose

500–1000 mcg

Frequency

once daily during loading, then every 2-3 days

Cycle Length

The FDA-approved implant (Scenesse) lasts ~60 days; research protocols vary from 2-4 weeks

Administration Routes:
subcutaneous

Benefits

  • FDA-approved (as implant) for erythropoietic protoporphyria (EPP)
  • Increases eumelanin production for photoprotective tanning
  • More selective melanocortin profile than Melanotan II
  • Mild pro-sexual effects through partial MC4R activation
  • Potential photoprotective benefit against UV-induced DNA damage

Side Effects

Nausea (milder than Melanotan II)mild
Facial flushingmild
Darkening of existing nevi (moles)mild
Headachemild
Injection site reactions or implant site discomfortmild

Mechanism of Action

1

Potently and selectively agonizes MC1R on melanocytes, stimulating eumelanin synthesis via cAMP/PKA/MITF pathway

2

Partial agonism at MC4R contributes to mild pro-sexual and anorexigenic effects

3

Norleucine-4 and D-Phe-7 substitutions prevent oxidation and enzymatic degradation, increasing stability over native alpha-MSH

Contraindications

Do not use this peptide if any of the following apply:

  • History of melanoma or dysplastic nevus syndrome
  • Severe hepatic impairment
  • Pregnancy or breastfeeding
  • Known hypersensitivity to afamelanotide

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration2-4 weeks

Note: Protect from light. Do not freeze reconstituted solution.

Research Summary

Preclinical

Afamelanotide (Melanotan I) was FDA-approved in October 2019 under the brand name Scenesse as a subcutaneous implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). It was previously approved in the EU in 2014. Clinical trials demonstrated significant increases in pain-free time in sunlight. Research has also explored its use in vitiligo, polymorphous light eruption, and actinic keratosis prevention. Its pro-sexual effects are milder than Melanotan II due to greater MC1R selectivity, but MC4R-mediated effects on libido have been documented.

Frequently Asked Questions

Common questions about Melanotan I

UK-Specific Information

Exclusive data points and guidance for UK residents using Melanotan I

UK Lab Testing

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With

Share on TikTok

Generate a trackable link to share this peptide information on TikTok